#Prostate_Cancer
Clarity Pharmaceuticals Receives First FDA Breakthrough Therapy Designation for Prostate Cancer Imaging#Australia#Sydney#Prostate_Cancer#Clarity_Pharmaceuticals#PSMA_PET
Clarity Pharmaceuticals Receives First FDA Breakthrough Therapy Designation for Prostate Cancer Imaging
Clarity Pharmaceuticals has gained FDA Breakthrough Therapy designation for 64Cu-SAR-bisPSMA in detecting prostate cancer recurrence, marking a significant milestone in cancer imaging.
third-news.com
November 12, 2026 at 2:21 PM
New Prostate Cancer Screening Guidelines Released by the American Cancer Society to Enhance Early Detection#United_States#Atlanta#Prostate_Cancer#American_Cancer_Society#PSA_Testing
New Prostate Cancer Screening Guidelines Released by the American Cancer Society to Enhance Early Detection
The American Cancer Society has updated its prostate cancer screening guidelines to improve early detection and save lives. Regular PSA testing is emphasized for at-risk men.
third-news.com
November 13, 2026 at 12:27 AM
Actinium Pharmaceuticals Set to Host Webinar Featuring Expert Insights on ATNM-400 and Its Potential in Prostate Cancer Treatment#United_States#New_York#Prostate_Cancer#Actinium_Pharmaceuticals#ATNM-400
Actinium Pharmaceuticals Set to Host Webinar Featuring Expert Insights on ATNM-400 and Its Potential in Prostate Cancer Treatment
Join Actinium Pharmaceuticals for an insightful webinar discussing ATNM-400, a new HER3-targeted radiotherapy, featuring prostate cancer experts and latest findings.
third-news.com
November 12, 2026 at 1:50 PM
Clarity Pharmaceuticals Achieves Recruitment Milestone in Phase III CLARIFY Trial for Prostate Cancer Imaging#Australia#Sydney#Prostate_Cancer#Clarity_Pharmaceuticals #64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Achieves Recruitment Milestone in Phase III CLARIFY Trial for Prostate Cancer Imaging
Clarity Pharmaceuticals has successfully recruited 383 participants for its Phase III CLARIFY trial, aimed at improving prostate cancer imaging with 64Cu-SAR-bisPSMA.
third-news.com
October 27, 2026 at 1:41 PM
Promising Results Reported by Full-Life Technologies for FL-020 in Phase 1 Study on Prostate Cancer#None#Madrid#Prostate_Cancer#Full-Life_Technologies#FL-020
Promising Results Reported by Full-Life Technologies for FL-020 in Phase 1 Study on Prostate Cancer
Preliminary safety and efficacy data for Full-Life Technologies' FL-020 in metastatic castration-resistant prostate cancer reveal significant PSA declines, leading to optimism for future treatments.
third-news.com
October 23, 2026 at 6:06 AM
Avenda Health Introduces Surgical Mode for Enhanced Prostate Cancer Management with AI Mapping#United_States#Culver_City#Prostate_Cancer#Avenda_Health#Unfold_AI
Avenda Health Introduces Surgical Mode for Enhanced Prostate Cancer Management with AI Mapping
Avenda Health unveils Surgery Mode in Unfold AI for real-time 3D cancer mapping, enhancing surgical precision in prostate cancer treatments.
third-news.com
October 20, 2026 at 1:32 PM
Actinium Pharmaceuticals Reveals Groundbreaking Study at EANM 2026 on ATNM-400 for Prostate Cancer#United_States#New_York#Prostate_Cancer#Actinium#ATNM-400
Actinium Pharmaceuticals Reveals Groundbreaking Study at EANM 2026 on ATNM-400 for Prostate Cancer
Actinium Pharmaceuticals announced exciting early findings from a Phase 1 trial of ATNM-400 at EANM 2026, marking a potential breakthrough in prostate cancer treatment.
third-news.com
October 15, 2026 at 1:00 PM
SOPHiA GENETICS and Myriad Collaborate to Enhance Prostate Cancer Diagnostics#USA#Boston#Prostate_Cancer#SOPHiA_GENETICS#Myriad_Genetics
SOPHiA GENETICS and Myriad Collaborate to Enhance Prostate Cancer Diagnostics
SOPHiA GENETICS and Myriad Genetics team up to enhance prostate cancer diagnostics by developing innovative genomic instability scoring technology.
third-news.com
October 8, 2026 at 1:43 PM
5Q Spectra to Present Promising Prostate Cancer Blood Test at Davos Healthcare#United_States#New_York#Prostate_Cancer #5Q_Spectra#PSB_Blood_Test
5Q Spectra to Present Promising Prostate Cancer Blood Test at Davos Healthcare
At Davos Healthcare, 5Q Spectra will unveil its clinical program for the PSB blood test, aimed at revolutionizing prostate cancer detection and management.
third-news.com
September 14, 2026 at 12:43 PM
We are proud to support @prostatecanceruk.bsky.social & this Father's Day we are campaigning & donating to their charity as well as working hard to get men talking. See the video of our founder Neil's talking about this and his own story here. fromyoutome.com/prostate_cancer
Supporting Prostate Cancer UK - Our 2025 Campaign | FROM YOU TO ME
Join our mission to support Prostate Cancer UK. Learn how we’re donating 10% of profits from our Journals of a Lifetime range.
fromyoutome.com
May 14, 2025 at 3:39 PM
"A new study, led by experts from University College London (UCL) and University College London Hospitals NHS Foundation Trust (UCLH), has found that the NeuroSafe method nearly doubles the proportion of men... " #prostate_cancer

www.independent.co.uk/news/health/...
Breakthrough in prostate cancer treatment offers hope for erectile function
The method nearly doubles the proportion of men who maintain erectile function after prostate cancer surgery
www.independent.co.uk
June 8, 2025 at 8:59 AM